343 related articles for article (PubMed ID: 25538262)
1. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
Min L; Hodi FS; Giobbie-Hurder A; Ott PA; Luke JJ; Donahue H; Davis M; Carroll RS; Kaiser UB
Clin Cancer Res; 2015 Feb; 21(4):749-55. PubMed ID: 25538262
[TBL] [Abstract][Full Text] [Related]
2. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy.
Lammert A; Schneider HJ; Bergmann T; Benck U; Krämer BK; Gärtner R; Metzner C; Schöfl C; Berking C
Exp Clin Endocrinol Diabetes; 2013 Nov; 121(10):581-7. PubMed ID: 24122241
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
[TBL] [Abstract][Full Text] [Related]
4. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.
Horvat TZ; Adel NG; Dang TO; Momtaz P; Postow MA; Callahan MK; Carvajal RD; Dickson MA; D'Angelo SP; Woo KM; Panageas KS; Wolchok JD; Chapman PB
J Clin Oncol; 2015 Oct; 33(28):3193-8. PubMed ID: 26282644
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
[TBL] [Abstract][Full Text] [Related]
6. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
Faje AT; Sullivan R; Lawrence D; Tritos NA; Fadden R; Klibanski A; Nachtigall L
J Clin Endocrinol Metab; 2014 Nov; 99(11):4078-85. PubMed ID: 25078147
[TBL] [Abstract][Full Text] [Related]
7. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
[TBL] [Abstract][Full Text] [Related]
8. Hyponatremia associated with Ipilimumab-induced hypophysitis.
Barnard ZR; Walcott BP; Kahle KT; Nahed BV; Coumans JV
Med Oncol; 2012 Mar; 29(1):374-7. PubMed ID: 21264545
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab-induced hypophysitis: review of the literature.
Araujo PB; Coelho MC; Arruda M; Gadelha MR; Neto LV
J Endocrinol Invest; 2015 Nov; 38(11):1159-66. PubMed ID: 25957829
[TBL] [Abstract][Full Text] [Related]
10. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
Ryder M; Callahan M; Postow MA; Wolchok J; Fagin JA
Endocr Relat Cancer; 2014 Apr; 21(2):371-81. PubMed ID: 24610577
[TBL] [Abstract][Full Text] [Related]
11. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
van der Hiel B; Blank CU; Haanen JB; Stokkel MP
Clin Nucl Med; 2013 Apr; 38(4):e182-4. PubMed ID: 23455528
[TBL] [Abstract][Full Text] [Related]
12. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
Vazquez A
Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
[TBL] [Abstract][Full Text] [Related]
13. [Lymphocytic hypophysitis due to ipilimumap therapy].
Thomsen HH
Ugeskr Laeger; 2012 Jun; 174(26):1829-30. PubMed ID: 22735122
[TBL] [Abstract][Full Text] [Related]
14. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
Faje AT; Lawrence D; Flaherty K; Freedman C; Fadden R; Rubin K; Cohen J; Sullivan RJ
Cancer; 2018 Sep; 124(18):3706-3714. PubMed ID: 29975414
[TBL] [Abstract][Full Text] [Related]
15. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.
Marlier J; Cocquyt V; Brochez L; Van Belle S; Kruse V
Endocrine; 2014 Dec; 47(3):878-83. PubMed ID: 24554495
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab-induced hypophysitis: MR imaging findings.
Carpenter KJ; Murtagh RD; Lilienfeld H; Weber J; Murtagh FR
AJNR Am J Neuroradiol; 2009 Oct; 30(9):1751-3. PubMed ID: 19474123
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.
Papavasileiou E; Prasad S; Freitag SK; Sobrin L; Lobo AM
Ocul Immunol Inflamm; 2016; 24(2):140-6. PubMed ID: 25760920
[TBL] [Abstract][Full Text] [Related]
19. Ipilimumab-induced hypophysitis, a single academic center experience.
Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R
Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112
[TBL] [Abstract][Full Text] [Related]
20. [Ipilimumab-induced hypophysitis].
Schleder S; Schreml S; Heiss P
Rofo; 2013 Mar; 185(3):268-9. PubMed ID: 23154861
[No Abstract] [Full Text] [Related]
[Next] [New Search]
